Banco Bilbao Vizcaya Argentaria SA (BBVA) Stock Price Today
Aura AI Summary
Key Stats
- $159.11BMarket Cap
- 1,205,418Volume
- FinancialsSector
- $29.6452W High
- $18.0452W Low
- 80 DaysTypical Hold Time
- $135.27BEnterprise Value
- 3.74%Div Yield
- 1% Sell | 99% BuyTrading Activity
Track Banco Bilbao Vizcaya Argentaria SA (BBVA) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Banco Bilbao Vizcaya Argentaria SA has traded between a low of $18.04 and a high of $29.64, highlighting its annual price range. Buy and sell Banco Bilbao Vizcaya Argentaria SA shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Banco Bilbao Vizcaya Argentaria SA
Despite its Spanish origins, BBVA generates three quarters of its profits in emerging markets, especially Mexico that contributes nearly half of BBVA's net profit. BBVA is overwhelmingly a retail and commercial bank with corporate and investment banking forming a smaller part of the overall business.
Most Recent News
La-Z-Boy director Janet Kerr sells 3,653 shares for $116,000.
Janet Kerr, a director at La-Z-Boy, has sold 3,653 shares of the company, generating $116,000 from the transaction. This sale could indicate a personal financial decision or portfolio adjustment, but it may also attract investor attention regarding i...

AI and crypto stocks surge as TJGC plans AI expansion and FWDI updates SkyAI acquisition offer
Shares of TJGC Group Limited jumped nearly 54% after announcing plans to expand into AI hardware, led by new leadership in electronics manufacturing. Forward Industries rose 24% following an updated acquisition proposal for SkyAI, offering a 50% prem...

Replimune sued for allegedly misleading investors on cancer drug trial data, shares plunge after FDA rejection.
Replimune Group faces a class action lawsuit alleging it misled investors about the efficacy and viability of its lead cancer drug candidate RP1. The FDA rejected Replimune's Biologics License Application (BLA) for RP1 combined with nivolumab due to ...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.